TOL:NYSEToll Brothers, Inc. Analysis
Data as of 2026-05-27 - not real-time
$137.85
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Toll Brothers is trading at $137.85, comfortably above its 20‑day SMA of $135.45 but slightly under the 50‑day SMA of $137.99, indicating short‑term momentum while still respecting a broader bearish bias (price below the 200‑day SMA of $140.02). The MACD histogram has turned positive (0.40) and the signal line is bullish, while the RSI sits at a neutral 52, suggesting the downside pressure may be easing. On the valuation side, the stock trades at a forward PE of 9.75 and a price‑to‑book of 1.55, well below the sector average, and analysts’ consensus target of $163.8 implies an upside of roughly 19%. Earnings recently beat expectations, with EPS rising to $13.16 and a modest dividend yield of 0.73% supported by a low payout ratio of 7.7%, underscoring dividend sustainability. However, revenue contracted 7.6% YoY, reflecting the cyclical nature of the luxury home market, and the 30‑day volatility remains elevated at 44% with a beta above 1.2. Recent news highlights a strong Q1 performance, an 8.3% share price rally, and an upgraded full‑year delivery guidance of 10,400‑10,700 homes, reinforcing confidence in the company’s execution.
Given the blend of attractive valuation, resilient margins (operating margin 15.1%, profit margin 11.7%), manageable leverage (debt‑to‑equity ~33%), and supportive analyst sentiment (Buy recommendation from 16 analysts), the stock appears positioned for a multi‑month upside, provided macro‑economic conditions for luxury housing remain stable.
Given the blend of attractive valuation, resilient margins (operating margin 15.1%, profit margin 11.7%), manageable leverage (debt‑to‑equity ~33%), and supportive analyst sentiment (Buy recommendation from 16 analysts), the stock appears positioned for a multi‑month upside, provided macro‑economic conditions for luxury housing remain stable.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat and 8.3% share price rally
- Positive MACD crossover amid overall bearish trend
- High 30‑day volatility and beta above market
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Raised FY2026 delivery guidance and full‑year outlook
- Attractive valuation multiples (PE ~10, forward PE <10)
- Low dividend payout ratio indicating sustainability
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong brand in the luxury residential segment
- Solid balance sheet with manageable debt and cash reserves
- Long‑term upside to analyst target price and demographic tailwinds
Key Metrics & Analysis
Financial Health
Revenue Growth-7.60%
Profit Margin11.66%
P/E Ratio10.5
ROE15.66%
ROA7.53%
Debt/Equity32.80
P/B Ratio1.6
Technical Analysis
TrendBearish
RSI52.0
Support$123.15
Resistance$148.77
MA 20$135.45
MA 50$137.99
MA 200$140.02
MACDBullish
VolumeIncreasing
Fear & Greed Index91.29
Valuation
Target Price$163.81
Upside/Downside18.83%
GradeUndervalued
TypeBlend
Dividend Yield0.73%
Risk Assessment
Beta1.28
Volatility43.77%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.